Immetas Therapeutics

Immetas Therapeutics is a private, preclinical-stage biotech targeting the nexus of aging and chronic inflammation. The company's scientific premise is that chronic low-grade inflammation is a fundamental driver of aging and age-related diseases, including cancer and autoimmune disorders. Leveraging emerging research from labs like the Sinclair Lab, Immetas aims to develop therapeutics that modulate innate and adaptive immune responses. Its approach is to translate abundant clinical evidence on immune-targeting drugs into novel treatments for a broad range of age-associated conditions.

A knowledge-driven development strategy based on the inflammaging hypothesis. Leverages emerging research on aging pathways that converge on inflammation and abundant clinical data from existing immunotherapies to develop novel biologics and small molecules that modulate innate and adaptive immune responses.

Competition is intense from large pharma and biotechs in both immunology and oncology. The specific niche of 'inflammaging' is emerging but attracting increased interest, placing Immetas against other geroscience startups and established companies exploring immune-metabolism and senescence.